Unmasking the Osteoinductive Effects of a G‐Protein‐Coupled Receptor (GPCR) Kinase (GRK) Inhibitor by Treatment With PTH(1–34)

The effects of GPCR systems in bone are regulated by a family of enzymes termed GRKs. We found that (1) GRK inhibition in osteoblasts has age‐dependent effects on bone mass, and (2) the anabolic actions of GRK inhibition are revealed by treatment with PTH(1–34). Introduction: The effects of G‐protei...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of bone and mineral research 2004-10, Vol.19 (10), p.1661-1670
Hauptverfasser: Wang, Liming, Quarles, L Darryl, Spurney, Robert F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1670
container_issue 10
container_start_page 1661
container_title Journal of bone and mineral research
container_volume 19
creator Wang, Liming
Quarles, L Darryl
Spurney, Robert F
description The effects of GPCR systems in bone are regulated by a family of enzymes termed GRKs. We found that (1) GRK inhibition in osteoblasts has age‐dependent effects on bone mass, and (2) the anabolic actions of GRK inhibition are revealed by treatment with PTH(1–34). Introduction: The effects of G‐protein‐coupled receptor (GPCR) systems in bone are modulated by a family of enzymes termed GPCR kinases (GRKs). These enzymes directly phosphorylate GPCR substrate and desensitize receptor signaling. We previously found that expression of a GRK inhibitor in osteoblasts using transgenic (TG) technologies enhanced bone remodeling, and in turn, increased BMD in 6‐week‐old TG mice compared with non‐TG littermate controls, presumably because of enhanced GPCR function. The aim of this study was to determine the age‐dependent effects of the transgene. Materials and Methods: BMD was monitored in TG mice and in controls at 6‐week, 3‐month, and 6‐month time‐points. To determine if the transgene enhanced responsiveness of bone to parathyroid hormone (PTH), we measured cyclic adenosine monophosphate (cAMP) generation by mouse calvaria ex vivo as well as the effects of treatment with PTH(1–34) on BMD, bone histomorphometry, and expression of the PTH‐responsive gene RANKL in both TG mice and non‐TG controls. Results: Consistent with our previous findings, we found that BMD was increased in TG mice compared with controls at 6 weeks of age. The increase in BMD was most prominent in trabecular‐rich lumbar spine and was not observed in cortical bone of the femoral shaft. In contrast to younger animals, however, BMD in older TG mice was not statistically different compared with non‐TG mice at 3 months of age and was similar to non‐TG animals at 6 months of age. The GRK inhibitor seemed to promote GPCR activation in older mice, however, because (1) PTH‐induced cAMP generation by mouse calvaria ex vivo was enhanced in TG mice compared with controls, (2) GRK inhibition increased responsiveness of lumbar spine to the osteoinductive actions of PTH(1–34), and (3) the enhanced anabolic effect of PTH(1–34) was associated with increased expression of the PTH‐responsive gene RANKL in calvaria of the TG animals. Bone histomorphometry confirmed that PTH(1–34) increased trabecular bone volume in TG mice and found that this increase in bone mass was caused by enhanced bone formation, predominantly as a result of an increase in the mineral apposition rate (MAR). Conclusions: These data suggest that t
doi_str_mv 10.1359/JBMR.040708
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66857542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66857542</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4339-93b7b0796381ed36cba2c9e17d583fe88b7859f854dc9d69d72f7719aaeff0463</originalsourceid><addsrcrecordid>eNqF0c1uEzEQB3ALgWgonLgjX0CN0BY7_j7SqKSlRY2iVBxXXu-YGPYjXXtBufXQB6jEG_ZJ2JBIvcFpZjQ_zRz-CL2m5JgyYT58PvmyOCacKKKfoBEVE5ZxqelTNCJa84xwRg_Qixi_E0KkkPI5OqCCCSEkHaG766a28UdovuG0AnwVE7ShKXuXwk_Ap96DSxG3Hls8e7i9n3dtgtAM3bTt1xWUeAEO1qnt8NFsPl2M8UVobIRhWlyM8XmzCkXYbosNXnZgUw1Nwl9DWuH58uyIPtz-Znz8Ej3ztorwal8P0fWn0-X0LLu8mp1PP15mjjNmMsMKVRBlJNMUSiZdYSfOAFWl0MyD1oXSwngteOlMKU2pJl4paqwF7wmX7BC9291dd-1NDzHldYgOqso20PYxl1ILJfjkv5AqpTSRZoDvd9B1bYwd-Hzdhdp2m5ySfJtOvk0n36Uz6Df7s31RQ_lo93EM4O0e2Ohs5TvbuBAfnaSSC6EGp3buV6hg86-ff3shBaGGEmLYHzy5qDY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17778069</pqid></control><display><type>article</type><title>Unmasking the Osteoinductive Effects of a G‐Protein‐Coupled Receptor (GPCR) Kinase (GRK) Inhibitor by Treatment With PTH(1–34)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Wang, Liming ; Quarles, L Darryl ; Spurney, Robert F</creator><creatorcontrib>Wang, Liming ; Quarles, L Darryl ; Spurney, Robert F</creatorcontrib><description>The effects of GPCR systems in bone are regulated by a family of enzymes termed GRKs. We found that (1) GRK inhibition in osteoblasts has age‐dependent effects on bone mass, and (2) the anabolic actions of GRK inhibition are revealed by treatment with PTH(1–34). Introduction: The effects of G‐protein‐coupled receptor (GPCR) systems in bone are modulated by a family of enzymes termed GPCR kinases (GRKs). These enzymes directly phosphorylate GPCR substrate and desensitize receptor signaling. We previously found that expression of a GRK inhibitor in osteoblasts using transgenic (TG) technologies enhanced bone remodeling, and in turn, increased BMD in 6‐week‐old TG mice compared with non‐TG littermate controls, presumably because of enhanced GPCR function. The aim of this study was to determine the age‐dependent effects of the transgene. Materials and Methods: BMD was monitored in TG mice and in controls at 6‐week, 3‐month, and 6‐month time‐points. To determine if the transgene enhanced responsiveness of bone to parathyroid hormone (PTH), we measured cyclic adenosine monophosphate (cAMP) generation by mouse calvaria ex vivo as well as the effects of treatment with PTH(1–34) on BMD, bone histomorphometry, and expression of the PTH‐responsive gene RANKL in both TG mice and non‐TG controls. Results: Consistent with our previous findings, we found that BMD was increased in TG mice compared with controls at 6 weeks of age. The increase in BMD was most prominent in trabecular‐rich lumbar spine and was not observed in cortical bone of the femoral shaft. In contrast to younger animals, however, BMD in older TG mice was not statistically different compared with non‐TG mice at 3 months of age and was similar to non‐TG animals at 6 months of age. The GRK inhibitor seemed to promote GPCR activation in older mice, however, because (1) PTH‐induced cAMP generation by mouse calvaria ex vivo was enhanced in TG mice compared with controls, (2) GRK inhibition increased responsiveness of lumbar spine to the osteoinductive actions of PTH(1–34), and (3) the enhanced anabolic effect of PTH(1–34) was associated with increased expression of the PTH‐responsive gene RANKL in calvaria of the TG animals. Bone histomorphometry confirmed that PTH(1–34) increased trabecular bone volume in TG mice and found that this increase in bone mass was caused by enhanced bone formation, predominantly as a result of an increase in the mineral apposition rate (MAR). Conclusions: These data suggest that the anabolic effects of GRK inhibition are age dependent. The osteoinductive actions of the GRK inhibitor are, however, unmasked by treatment with PTH(1–34).</description><identifier>ISSN: 0884-0431</identifier><identifier>EISSN: 1523-4681</identifier><identifier>DOI: 10.1359/JBMR.040708</identifier><identifier>PMID: 15355561</identifier><identifier>CODEN: JBMREJ</identifier><language>eng</language><publisher>Washington, DC: John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)</publisher><subject>Aging ; Amino Acids - urine ; Animals ; beta-Adrenergic Receptor Kinases ; Biological and medical sciences ; Biomarkers - urine ; Bone and Bones - metabolism ; Bone Density - drug effects ; Carrier Proteins - genetics ; Carrier Proteins - metabolism ; Cyclic AMP - metabolism ; Cyclic AMP-Dependent Protein Kinases - antagonists &amp; inhibitors ; Cyclic AMP-Dependent Protein Kinases - metabolism ; Cyclic AMP-Dependent Protein Kinases - physiology ; Fundamental and applied biological sciences. Psychology ; Glycoproteins - genetics ; Glycoproteins - metabolism ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - metabolism ; Mice ; Mice, Transgenic ; osteoblast ; Osteoblasts - metabolism ; osteoclast ; Osteoclasts - drug effects ; Osteoprotegerin ; parathyroid hormone ; Parathyroid Hormone - pharmacology ; parathyroid hormone/parathyroid‐related peptide ; Peptide Fragments - pharmacology ; RANK Ligand ; receptor ; Receptor Activator of Nuclear Factor-kappa B ; Receptors, Cytoplasmic and Nuclear - genetics ; Receptors, Cytoplasmic and Nuclear - metabolism ; Receptors, Parathyroid Hormone - metabolism ; Receptors, Tumor Necrosis Factor ; RNA, Messenger - metabolism ; Skeleton and joints ; Vertebrates: osteoarticular system, musculoskeletal system</subject><ispartof>Journal of bone and mineral research, 2004-10, Vol.19 (10), p.1661-1670</ispartof><rights>Copyright © 2004 ASBMR</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4339-93b7b0796381ed36cba2c9e17d583fe88b7859f854dc9d69d72f7719aaeff0463</citedby><cites>FETCH-LOGICAL-c4339-93b7b0796381ed36cba2c9e17d583fe88b7859f854dc9d69d72f7719aaeff0463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1359%2FJBMR.040708$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1359%2FJBMR.040708$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16164557$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15355561$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Liming</creatorcontrib><creatorcontrib>Quarles, L Darryl</creatorcontrib><creatorcontrib>Spurney, Robert F</creatorcontrib><title>Unmasking the Osteoinductive Effects of a G‐Protein‐Coupled Receptor (GPCR) Kinase (GRK) Inhibitor by Treatment With PTH(1–34)</title><title>Journal of bone and mineral research</title><addtitle>J Bone Miner Res</addtitle><description>The effects of GPCR systems in bone are regulated by a family of enzymes termed GRKs. We found that (1) GRK inhibition in osteoblasts has age‐dependent effects on bone mass, and (2) the anabolic actions of GRK inhibition are revealed by treatment with PTH(1–34). Introduction: The effects of G‐protein‐coupled receptor (GPCR) systems in bone are modulated by a family of enzymes termed GPCR kinases (GRKs). These enzymes directly phosphorylate GPCR substrate and desensitize receptor signaling. We previously found that expression of a GRK inhibitor in osteoblasts using transgenic (TG) technologies enhanced bone remodeling, and in turn, increased BMD in 6‐week‐old TG mice compared with non‐TG littermate controls, presumably because of enhanced GPCR function. The aim of this study was to determine the age‐dependent effects of the transgene. Materials and Methods: BMD was monitored in TG mice and in controls at 6‐week, 3‐month, and 6‐month time‐points. To determine if the transgene enhanced responsiveness of bone to parathyroid hormone (PTH), we measured cyclic adenosine monophosphate (cAMP) generation by mouse calvaria ex vivo as well as the effects of treatment with PTH(1–34) on BMD, bone histomorphometry, and expression of the PTH‐responsive gene RANKL in both TG mice and non‐TG controls. Results: Consistent with our previous findings, we found that BMD was increased in TG mice compared with controls at 6 weeks of age. The increase in BMD was most prominent in trabecular‐rich lumbar spine and was not observed in cortical bone of the femoral shaft. In contrast to younger animals, however, BMD in older TG mice was not statistically different compared with non‐TG mice at 3 months of age and was similar to non‐TG animals at 6 months of age. The GRK inhibitor seemed to promote GPCR activation in older mice, however, because (1) PTH‐induced cAMP generation by mouse calvaria ex vivo was enhanced in TG mice compared with controls, (2) GRK inhibition increased responsiveness of lumbar spine to the osteoinductive actions of PTH(1–34), and (3) the enhanced anabolic effect of PTH(1–34) was associated with increased expression of the PTH‐responsive gene RANKL in calvaria of the TG animals. Bone histomorphometry confirmed that PTH(1–34) increased trabecular bone volume in TG mice and found that this increase in bone mass was caused by enhanced bone formation, predominantly as a result of an increase in the mineral apposition rate (MAR). Conclusions: These data suggest that the anabolic effects of GRK inhibition are age dependent. The osteoinductive actions of the GRK inhibitor are, however, unmasked by treatment with PTH(1–34).</description><subject>Aging</subject><subject>Amino Acids - urine</subject><subject>Animals</subject><subject>beta-Adrenergic Receptor Kinases</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - urine</subject><subject>Bone and Bones - metabolism</subject><subject>Bone Density - drug effects</subject><subject>Carrier Proteins - genetics</subject><subject>Carrier Proteins - metabolism</subject><subject>Cyclic AMP - metabolism</subject><subject>Cyclic AMP-Dependent Protein Kinases - antagonists &amp; inhibitors</subject><subject>Cyclic AMP-Dependent Protein Kinases - metabolism</subject><subject>Cyclic AMP-Dependent Protein Kinases - physiology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glycoproteins - genetics</subject><subject>Glycoproteins - metabolism</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>osteoblast</subject><subject>Osteoblasts - metabolism</subject><subject>osteoclast</subject><subject>Osteoclasts - drug effects</subject><subject>Osteoprotegerin</subject><subject>parathyroid hormone</subject><subject>Parathyroid Hormone - pharmacology</subject><subject>parathyroid hormone/parathyroid‐related peptide</subject><subject>Peptide Fragments - pharmacology</subject><subject>RANK Ligand</subject><subject>receptor</subject><subject>Receptor Activator of Nuclear Factor-kappa B</subject><subject>Receptors, Cytoplasmic and Nuclear - genetics</subject><subject>Receptors, Cytoplasmic and Nuclear - metabolism</subject><subject>Receptors, Parathyroid Hormone - metabolism</subject><subject>Receptors, Tumor Necrosis Factor</subject><subject>RNA, Messenger - metabolism</subject><subject>Skeleton and joints</subject><subject>Vertebrates: osteoarticular system, musculoskeletal system</subject><issn>0884-0431</issn><issn>1523-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0c1uEzEQB3ALgWgonLgjX0CN0BY7_j7SqKSlRY2iVBxXXu-YGPYjXXtBufXQB6jEG_ZJ2JBIvcFpZjQ_zRz-CL2m5JgyYT58PvmyOCacKKKfoBEVE5ZxqelTNCJa84xwRg_Qixi_E0KkkPI5OqCCCSEkHaG766a28UdovuG0AnwVE7ShKXuXwk_Ap96DSxG3Hls8e7i9n3dtgtAM3bTt1xWUeAEO1qnt8NFsPl2M8UVobIRhWlyM8XmzCkXYbosNXnZgUw1Nwl9DWuH58uyIPtz-Znz8Ej3ztorwal8P0fWn0-X0LLu8mp1PP15mjjNmMsMKVRBlJNMUSiZdYSfOAFWl0MyD1oXSwngteOlMKU2pJl4paqwF7wmX7BC9291dd-1NDzHldYgOqso20PYxl1ILJfjkv5AqpTSRZoDvd9B1bYwd-Hzdhdp2m5ySfJtOvk0n36Uz6Df7s31RQ_lo93EM4O0e2Ohs5TvbuBAfnaSSC6EGp3buV6hg86-ff3shBaGGEmLYHzy5qDY</recordid><startdate>200410</startdate><enddate>200410</enddate><creator>Wang, Liming</creator><creator>Quarles, L Darryl</creator><creator>Spurney, Robert F</creator><general>John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)</general><general>American Society for Bone and Mineral Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>200410</creationdate><title>Unmasking the Osteoinductive Effects of a G‐Protein‐Coupled Receptor (GPCR) Kinase (GRK) Inhibitor by Treatment With PTH(1–34)</title><author>Wang, Liming ; Quarles, L Darryl ; Spurney, Robert F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4339-93b7b0796381ed36cba2c9e17d583fe88b7859f854dc9d69d72f7719aaeff0463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aging</topic><topic>Amino Acids - urine</topic><topic>Animals</topic><topic>beta-Adrenergic Receptor Kinases</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - urine</topic><topic>Bone and Bones - metabolism</topic><topic>Bone Density - drug effects</topic><topic>Carrier Proteins - genetics</topic><topic>Carrier Proteins - metabolism</topic><topic>Cyclic AMP - metabolism</topic><topic>Cyclic AMP-Dependent Protein Kinases - antagonists &amp; inhibitors</topic><topic>Cyclic AMP-Dependent Protein Kinases - metabolism</topic><topic>Cyclic AMP-Dependent Protein Kinases - physiology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glycoproteins - genetics</topic><topic>Glycoproteins - metabolism</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>osteoblast</topic><topic>Osteoblasts - metabolism</topic><topic>osteoclast</topic><topic>Osteoclasts - drug effects</topic><topic>Osteoprotegerin</topic><topic>parathyroid hormone</topic><topic>Parathyroid Hormone - pharmacology</topic><topic>parathyroid hormone/parathyroid‐related peptide</topic><topic>Peptide Fragments - pharmacology</topic><topic>RANK Ligand</topic><topic>receptor</topic><topic>Receptor Activator of Nuclear Factor-kappa B</topic><topic>Receptors, Cytoplasmic and Nuclear - genetics</topic><topic>Receptors, Cytoplasmic and Nuclear - metabolism</topic><topic>Receptors, Parathyroid Hormone - metabolism</topic><topic>Receptors, Tumor Necrosis Factor</topic><topic>RNA, Messenger - metabolism</topic><topic>Skeleton and joints</topic><topic>Vertebrates: osteoarticular system, musculoskeletal system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Liming</creatorcontrib><creatorcontrib>Quarles, L Darryl</creatorcontrib><creatorcontrib>Spurney, Robert F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of bone and mineral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Liming</au><au>Quarles, L Darryl</au><au>Spurney, Robert F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unmasking the Osteoinductive Effects of a G‐Protein‐Coupled Receptor (GPCR) Kinase (GRK) Inhibitor by Treatment With PTH(1–34)</atitle><jtitle>Journal of bone and mineral research</jtitle><addtitle>J Bone Miner Res</addtitle><date>2004-10</date><risdate>2004</risdate><volume>19</volume><issue>10</issue><spage>1661</spage><epage>1670</epage><pages>1661-1670</pages><issn>0884-0431</issn><eissn>1523-4681</eissn><coden>JBMREJ</coden><abstract>The effects of GPCR systems in bone are regulated by a family of enzymes termed GRKs. We found that (1) GRK inhibition in osteoblasts has age‐dependent effects on bone mass, and (2) the anabolic actions of GRK inhibition are revealed by treatment with PTH(1–34). Introduction: The effects of G‐protein‐coupled receptor (GPCR) systems in bone are modulated by a family of enzymes termed GPCR kinases (GRKs). These enzymes directly phosphorylate GPCR substrate and desensitize receptor signaling. We previously found that expression of a GRK inhibitor in osteoblasts using transgenic (TG) technologies enhanced bone remodeling, and in turn, increased BMD in 6‐week‐old TG mice compared with non‐TG littermate controls, presumably because of enhanced GPCR function. The aim of this study was to determine the age‐dependent effects of the transgene. Materials and Methods: BMD was monitored in TG mice and in controls at 6‐week, 3‐month, and 6‐month time‐points. To determine if the transgene enhanced responsiveness of bone to parathyroid hormone (PTH), we measured cyclic adenosine monophosphate (cAMP) generation by mouse calvaria ex vivo as well as the effects of treatment with PTH(1–34) on BMD, bone histomorphometry, and expression of the PTH‐responsive gene RANKL in both TG mice and non‐TG controls. Results: Consistent with our previous findings, we found that BMD was increased in TG mice compared with controls at 6 weeks of age. The increase in BMD was most prominent in trabecular‐rich lumbar spine and was not observed in cortical bone of the femoral shaft. In contrast to younger animals, however, BMD in older TG mice was not statistically different compared with non‐TG mice at 3 months of age and was similar to non‐TG animals at 6 months of age. The GRK inhibitor seemed to promote GPCR activation in older mice, however, because (1) PTH‐induced cAMP generation by mouse calvaria ex vivo was enhanced in TG mice compared with controls, (2) GRK inhibition increased responsiveness of lumbar spine to the osteoinductive actions of PTH(1–34), and (3) the enhanced anabolic effect of PTH(1–34) was associated with increased expression of the PTH‐responsive gene RANKL in calvaria of the TG animals. Bone histomorphometry confirmed that PTH(1–34) increased trabecular bone volume in TG mice and found that this increase in bone mass was caused by enhanced bone formation, predominantly as a result of an increase in the mineral apposition rate (MAR). Conclusions: These data suggest that the anabolic effects of GRK inhibition are age dependent. The osteoinductive actions of the GRK inhibitor are, however, unmasked by treatment with PTH(1–34).</abstract><cop>Washington, DC</cop><pub>John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)</pub><pmid>15355561</pmid><doi>10.1359/JBMR.040708</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0884-0431
ispartof Journal of bone and mineral research, 2004-10, Vol.19 (10), p.1661-1670
issn 0884-0431
1523-4681
language eng
recordid cdi_proquest_miscellaneous_66857542
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current)
subjects Aging
Amino Acids - urine
Animals
beta-Adrenergic Receptor Kinases
Biological and medical sciences
Biomarkers - urine
Bone and Bones - metabolism
Bone Density - drug effects
Carrier Proteins - genetics
Carrier Proteins - metabolism
Cyclic AMP - metabolism
Cyclic AMP-Dependent Protein Kinases - antagonists & inhibitors
Cyclic AMP-Dependent Protein Kinases - metabolism
Cyclic AMP-Dependent Protein Kinases - physiology
Fundamental and applied biological sciences. Psychology
Glycoproteins - genetics
Glycoproteins - metabolism
Membrane Glycoproteins - genetics
Membrane Glycoproteins - metabolism
Mice
Mice, Transgenic
osteoblast
Osteoblasts - metabolism
osteoclast
Osteoclasts - drug effects
Osteoprotegerin
parathyroid hormone
Parathyroid Hormone - pharmacology
parathyroid hormone/parathyroid‐related peptide
Peptide Fragments - pharmacology
RANK Ligand
receptor
Receptor Activator of Nuclear Factor-kappa B
Receptors, Cytoplasmic and Nuclear - genetics
Receptors, Cytoplasmic and Nuclear - metabolism
Receptors, Parathyroid Hormone - metabolism
Receptors, Tumor Necrosis Factor
RNA, Messenger - metabolism
Skeleton and joints
Vertebrates: osteoarticular system, musculoskeletal system
title Unmasking the Osteoinductive Effects of a G‐Protein‐Coupled Receptor (GPCR) Kinase (GRK) Inhibitor by Treatment With PTH(1–34)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T19%3A18%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unmasking%20the%20Osteoinductive%20Effects%20of%20a%20G%E2%80%90Protein%E2%80%90Coupled%20Receptor%20(GPCR)%20Kinase%20(GRK)%20Inhibitor%20by%20Treatment%20With%20PTH(1%E2%80%9334)&rft.jtitle=Journal%20of%20bone%20and%20mineral%20research&rft.au=Wang,%20Liming&rft.date=2004-10&rft.volume=19&rft.issue=10&rft.spage=1661&rft.epage=1670&rft.pages=1661-1670&rft.issn=0884-0431&rft.eissn=1523-4681&rft.coden=JBMREJ&rft_id=info:doi/10.1359/JBMR.040708&rft_dat=%3Cproquest_cross%3E66857542%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17778069&rft_id=info:pmid/15355561&rfr_iscdi=true